Table 1 Descriptive statistics for patients included in this analysis and for all treated patients in the WISDOM population
From: Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial
Analysis | All treated | |
|---|---|---|
Patients, n | 360 | 2485 |
Males, n (%) | 284 (78.9) | 2049 (82.5) |
Age, mean years (SD) | 63.7 (8.5) | 63.8 (8.5) |
BMI, mean kg/m2 (SD) | 25.4 (5.4) | 25.2 (5.1) |
COPD duration, mean years (SD) | 8.7 (6.2) | 7.9 (6.2) |
Smoking status, n (%) | ||
Former smoker | 236 (65.6) | 1654 (66.6) |
Current smoker | 124 (34.4) | 831 (33.4) |
Smoking history, mean pack-years (SD) | 43.0 (21.6) | 45.0 (24.3) |
In-clinic post-bronchodilator FEV1, mean L (SD) | 0.923 (0.285) | 0.933 (0.297) |
In-clinic post-bronchodilator FEV1, mean % predicted (SD) | 32.7 (8.4) | 32.8 (9.1) |
Mean home-measured FEV1 in the period 6–8 weeks before index exacerbation, L (SD) | 0.907 (0.321) | N/A |
GOLD status, n (%) | ||
2 | 1 (0.3) | 1 (0.6) |
3 | 218 (60.6) | 101 (58.0) |
4 | 141 (39.2) | 72 (41.4) |
Number of patients included with a moderate exacerbation, n (%) | 317 (88.1) | N/A |
Number of patients included with a severe exacerbation, n (%) | 43 (11.9) | N/A |